Since divergent immunohistochemical findings have been reported for the FSHR protein expression and localization in ovarian cancer and prostate cancer [10,11,12,13,14,15,16,17,18,19], our goal was to validate FSHR as a drug target in human cancers. This evidence concerns the gene FSHR and ovarian cancer.